BMS’ Opdivo First EU Approved PD-1 Inhibitor

Bristol-Myers Squibb’s (BMS’) Opdivo for the use in treatment for advanced skin cancer (unresectable or metastatic melanoma in adults) has been the first PD-1 inhibitor to gain approval by the European regulators. Last summer, the inhibitor became the first PD-1 inhibitor to be approved in the world when Japanese regulators approved it. In the US,

Continue Reading

NICE Draft Guidance Rejects First-Line Yervoy for Advanced Melanoma

England and Wales’ cost regulator, NICE, have published draft guidance recommending that Bristol-Myers Squibb’s Yervoy (ipilimumab) should only be used by the National Health Service (NHS) for patients in clinical trials, as current evidence is lacking. The regulatory body has already approved the skin cancer drug as a second-line treatment for advanced malignant melanoma, but

Continue Reading

NICE Requests Further Information on Zelboraf

The National Institute for Health and Clinical Excellence (NICE) has issued a second draft guidance to Roche asking them to provide additional information on the use of their skin cancer drug, Zelboraf (vemurafenib). The request concerns Zelboraf’s use in the treatment of unresectable locally-advanced or metatastic BRAF V600 mutation-positive melanoma, for which NICE announced, in

Continue Reading

Disappointment as NICE Rejects Skin Cancer Drug

The conclusion by the UK’s National Institute for Health and Clinical Excellence (NICE) to reject Bristol-Myers Squibb’s new melanoma drug Yervoy has been greeted with disappointment by the company and patient groups. In a provisional draft guidance published earlier today, NICE decided against recommending payment by the UK’s National Health Service (NHS) of Yervoy (ipilimumab)

Continue Reading